Product
PY159
Aliases
PY159 Single agent dose expansion cohort, PY159 Single agent dose level 1, PY159 Single agent dose level 2, PY159 Single agent dose level 3 (4 other aliases)
1 clinical trial
8 indications
Indication
Advanced Solid TumorIndication
Gynecologic CancerIndication
Breast CancerIndication
Colorectal CancerIndication
Stomach AdenocarcinomaIndication
Adenocarcinoma of the LungIndication
Pancreatic CancerIndication
Head and Neck CancerClinical trial
A Phase 1a/1b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PY159 as a Single Agent and In Combination With Pembrolizumab in Subjects With Advanced Solid TumorsStatus: Terminated, Estimated PCD: 2023-08-25